Plasma and muscle myostatin in relation to type 2 diabetes.

<h4>Objective</h4>Myostatin is a secreted growth factor expressed in skeletal muscle tissue, which negatively regulates skeletal muscle mass. Recent animal studies suggest a role for myostatin in insulin resistance. We evaluated the possible metabolic role of myostatin in patients with t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claus Brandt, Anders R Nielsen, Christian P Fischer, Jakob Hansen, Bente K Pedersen, Peter Plomgaard
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/956a68aac7444831b127cf55b8407544
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:956a68aac7444831b127cf55b8407544
record_format	dspace
spelling	oai:doaj.org-article:956a68aac7444831b127cf55b84075442021-11-18T07:18:28ZPlasma and muscle myostatin in relation to type 2 diabetes.1932-620310.1371/journal.pone.0037236https://doaj.org/article/956a68aac7444831b127cf55b84075442012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22615949/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Myostatin is a secreted growth factor expressed in skeletal muscle tissue, which negatively regulates skeletal muscle mass. Recent animal studies suggest a role for myostatin in insulin resistance. We evaluated the possible metabolic role of myostatin in patients with type 2 diabetes and healthy controls.<h4>Design</h4>76 patients with type 2 diabetes and 92 control subjects were included in the study. They were matched for age, gender and BMI. Plasma samples and biopsies from the vastus lateralis muscle were obtained to assess plasma myostatin and expression of myostatin in skeletal muscle.<h4>Results</h4>Patients with type 2 diabetes had higher fasting glucose (8.9 versus 5.1 mmol/L, P<0.001), plasma insulin (68.2 versus 47.2 pmol/L, P<0.002) and HOMA2-IR (1.6 versus 0.9, P<0.0001) when compared to controls. Patients with type 2 diabetes had 1.4 (P<0.01) higher levels of muscle myostatin mRNA content than the control subjects. Plasma myostatin concentrations did not differ between patients with type 2 diabetes and controls. In healthy controls, muscle myostatin mRNA correlated with HOMA2-IR (r = 0.30, P<0.01), plasma IL-6 (r = 0.34, P<0.05) and VO2 max (r = -0.26, P<0.05), however, no correlations were observed in patients with type 2 diabetes.<h4>Conclusions</h4>This study supports the idea that myostatin may have a negative effect on metabolism. However, the metabolic effect of myostatin appears to be overruled by other factors in patients with type 2 diabetes.Claus BrandtAnders R NielsenChristian P FischerJakob HansenBente K PedersenPeter PlomgaardPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 5, p e37236 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Claus Brandt Anders R Nielsen Christian P Fischer Jakob Hansen Bente K Pedersen Peter Plomgaard Plasma and muscle myostatin in relation to type 2 diabetes.
description	<h4>Objective</h4>Myostatin is a secreted growth factor expressed in skeletal muscle tissue, which negatively regulates skeletal muscle mass. Recent animal studies suggest a role for myostatin in insulin resistance. We evaluated the possible metabolic role of myostatin in patients with type 2 diabetes and healthy controls.<h4>Design</h4>76 patients with type 2 diabetes and 92 control subjects were included in the study. They were matched for age, gender and BMI. Plasma samples and biopsies from the vastus lateralis muscle were obtained to assess plasma myostatin and expression of myostatin in skeletal muscle.<h4>Results</h4>Patients with type 2 diabetes had higher fasting glucose (8.9 versus 5.1 mmol/L, P<0.001), plasma insulin (68.2 versus 47.2 pmol/L, P<0.002) and HOMA2-IR (1.6 versus 0.9, P<0.0001) when compared to controls. Patients with type 2 diabetes had 1.4 (P<0.01) higher levels of muscle myostatin mRNA content than the control subjects. Plasma myostatin concentrations did not differ between patients with type 2 diabetes and controls. In healthy controls, muscle myostatin mRNA correlated with HOMA2-IR (r = 0.30, P<0.01), plasma IL-6 (r = 0.34, P<0.05) and VO2 max (r = -0.26, P<0.05), however, no correlations were observed in patients with type 2 diabetes.<h4>Conclusions</h4>This study supports the idea that myostatin may have a negative effect on metabolism. However, the metabolic effect of myostatin appears to be overruled by other factors in patients with type 2 diabetes.
format	article
author	Claus Brandt Anders R Nielsen Christian P Fischer Jakob Hansen Bente K Pedersen Peter Plomgaard
author_facet	Claus Brandt Anders R Nielsen Christian P Fischer Jakob Hansen Bente K Pedersen Peter Plomgaard
author_sort	Claus Brandt
title	Plasma and muscle myostatin in relation to type 2 diabetes.
title_short	Plasma and muscle myostatin in relation to type 2 diabetes.
title_full	Plasma and muscle myostatin in relation to type 2 diabetes.
title_fullStr	Plasma and muscle myostatin in relation to type 2 diabetes.
title_full_unstemmed	Plasma and muscle myostatin in relation to type 2 diabetes.
title_sort	plasma and muscle myostatin in relation to type 2 diabetes.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/956a68aac7444831b127cf55b8407544
work_keys_str_mv	AT clausbrandt plasmaandmusclemyostatininrelationtotype2diabetes AT andersrnielsen plasmaandmusclemyostatininrelationtotype2diabetes AT christianpfischer plasmaandmusclemyostatininrelationtotype2diabetes AT jakobhansen plasmaandmusclemyostatininrelationtotype2diabetes AT bentekpedersen plasmaandmusclemyostatininrelationtotype2diabetes AT peterplomgaard plasmaandmusclemyostatininrelationtotype2diabetes
_version_	1718423680138084352

Plasma and muscle myostatin in relation to type 2 diabetes.

Ejemplares similares